MTEX — what changed in the latest 10-Q
A section-by-section comparison of MTEX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2025-11-12
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +44 | −55 | ~16 | 17 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 4 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 1 |
| Risk factors | Text added/removed | +5 | −1 | 0 | 3 |
| Other information | No paragraph-level changes | 0 | 0 | 0 | 15 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
Our common stock trades on The Nasdaq Capital Markets (“Nasdaq”) under the symbol “MTEX.” As disclosed in our Annual Report on Form 10‑K filed on April 15, 2026, we are subject to certain Nasdaq listing requirements, including minimum stockholders’ equity requirements. On April 20, 2026, we received…
Consolidated net sales for the three months ended March 31, 2026 was $24.9 million, as compared to $26.6 million for the three months ended March 31, 2025, a decrease of $1.6 million, or 6.2%. The decline in revenues was principally due to slowing demand in certain regions we operate within.
Net income was $1.0 million for the three months ended March 31, 2026, or $0.49 per diluted share, as compared to a net loss of $1.5 million, or $0.80 per diluted share for the three months ended March 31, 2025.
Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025
The table below summarizes our consolidated operating results in dollars and as a percentage of net sales for the three months ended March 31, 2026 and 2025 (in thousands, except percentages):
Text removed vs the prior filing · source: 10-Q · 2025-11-12
Our common stock trades on The Nasdaq Capital Markets (“Nasdaq”) under the symbol “MTEX.”
Consolidated net sales for the three months ended September 30, 2025 was $29.2 million, as compared to $31.7 million for the three months ended September 30, 2024, a decrease of $$2.6 million, or 8.1%. Consolidated net sales for the nine months ended September 30, 2025 was $81.4 million, as compared…
Net realized and unrealized foreign currency loss for the nine months ended September 30, 2025 was $2.6 million. For the nine months ended September 30, 2024 foreign currency gains was $0.5 million.
Net income was $1.9 million for the three months ended September 30, 2025, or $1.01 per diluted share, as compared to a net loss of $0.3 million, or $0.17 per diluted share for the three months ended September 30, 2024.
Net loss was $3.9 million for the nine months ended September 30, 2025, or $2.06 per diluted share, as compared to net income of $0.2 million, or $0.12 per diluted share for the nine months ended September 30, 2024. Net realized and unrealized foreign currency loss of $2.6 million contributed to ove…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-14
Our failure to comply with The Nasdaq Capital Market continued listing standards may adversely affect the price and liquidity of our shares of common stock as well as our ability to raise capital in the future.
As disclosed in our Annual Report on Form 10‑K filed on April 15, 2026, we are subject to certain Nasdaq listing requirements, including minimum stockholders’ equity requirements. On April 20, 2026, we received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC …
Pursuant to Nasdaq rules, we have been provided a period of time to submit a plan to regain compliance. There can be no assurance that Nasdaq will accept our compliance plan or that we will be able to regain compliance within any applicable cure period. If we are unable to regain compliance, or if N…
A delisting could materially and adversely affect the liquidity and market price of our common stock, reduce analyst coverage and investor interest, and impair our ability to raise capital on acceptable terms, if at all. Any of these outcomes could have a material adverse effect on our business, fin…
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our 2025 Annual Report, which could materially affect our business or our consolidated financial position, results of operations, and cash flows. T…
Text removed vs the prior filing · source: 10-Q · 2025-11-12
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our 2024 Annual Report, which could materially affect our business or our consolidated financial position, results of operations, and cash flows. T…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice